IRIS
BOLZONI, Marina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.189
AS - Asia 4.152
EU - Europa 2.535
SA - Sud America 470
AF - Africa 259
Continente sconosciuto - Info sul continente non disponibili 9
Totale 11.614
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.064
SG - Singapore 1.394
CN - Cina 1.307
VN - Vietnam 566
SE - Svezia 501
IE - Irlanda 435
FI - Finlandia 429
BR - Brasile 366
IT - Italia 299
HK - Hong Kong 266
DE - Germania 252
TR - Turchia 211
ZA - Sudafrica 169
FR - Francia 134
BD - Bangladesh 119
NL - Olanda 107
CA - Canada 95
GB - Regno Unito 66
IN - India 64
UA - Ucraina 63
AR - Argentina 41
RU - Federazione Russa 40
CI - Costa d'Avorio 39
AT - Austria 36
BE - Belgio 30
JP - Giappone 30
RO - Romania 28
PH - Filippine 27
ES - Italia 25
TH - Thailandia 23
PL - Polonia 22
CZ - Repubblica Ceca 19
IQ - Iraq 17
UZ - Uzbekistan 16
LT - Lituania 15
MX - Messico 15
PK - Pakistan 15
KR - Corea 14
EC - Ecuador 12
CO - Colombia 11
VE - Venezuela 11
KZ - Kazakistan 10
AE - Emirati Arabi Uniti 8
EU - Europa 8
KE - Kenya 8
MA - Marocco 8
PY - Paraguay 8
TW - Taiwan 8
CL - Cile 7
ID - Indonesia 7
SA - Arabia Saudita 7
BO - Bolivia 6
EG - Egitto 6
MY - Malesia 6
SN - Senegal 5
UY - Uruguay 5
AL - Albania 4
BG - Bulgaria 4
CH - Svizzera 4
DZ - Algeria 4
IL - Israele 4
TN - Tunisia 4
CM - Camerun 3
DK - Danimarca 3
GT - Guatemala 3
JO - Giordania 3
KH - Cambogia 3
LB - Libano 3
MD - Moldavia 3
OM - Oman 3
PE - Perù 3
QA - Qatar 3
AO - Angola 2
AZ - Azerbaigian 2
BW - Botswana 2
CR - Costa Rica 2
CY - Cipro 2
DO - Repubblica Dominicana 2
EE - Estonia 2
ET - Etiopia 2
HN - Honduras 2
HR - Croazia 2
HU - Ungheria 2
IR - Iran 2
JM - Giamaica 2
LK - Sri Lanka 2
LV - Lettonia 2
PA - Panama 2
PS - Palestinian Territory 2
PT - Portogallo 2
SM - San Marino 2
SY - Repubblica araba siriana 2
AM - Armenia 1
BB - Barbados 1
BF - Burkina Faso 1
BY - Bielorussia 1
CG - Congo 1
GA - Gabon 1
GD - Grenada 1
GE - Georgia 1
Totale 11.602
Salva come PNG Salva come JPEG
Città #
Singapore 679
Ashburn 519
Dublin 433
Chandler 421
San Jose 363
Beijing 334
Santa Clara 307
Hong Kong 247
Dallas 204
Ho Chi Minh City 170
Izmir 165
Johannesburg 161
Dearborn 157
Parma 141
Nanjing 138
Jacksonville 135
Hanoi 133
New York 122
Los Angeles 107
Ann Arbor 106
Boardman 105
Shanghai 88
Princeton 86
Lauterbourg 84
Munich 76
San Mateo 59
Shenyang 59
Kunming 57
Toronto 51
Buffalo 49
Düsseldorf 42
Nanchang 42
Hebei 41
Abidjan 39
Helsinki 39
Columbus 38
Hefei 38
Wilmington 38
São Paulo 34
Jinan 33
Vienna 31
Brussels 30
Tianjin 29
Changsha 28
Jiaxing 28
Moscow 28
Haiphong 27
Kocaeli 27
Tokyo 26
Turku 24
Marseille 23
Focsani 22
Da Nang 20
Seattle 20
Warsaw 20
Des Moines 19
Milan 19
Montreal 18
Bremen 17
Hải Dương 17
Orem 17
Guangzhou 16
Stockholm 16
Brno 15
Chicago 15
Houston 15
Brooklyn 14
Council Bluffs 14
Tashkent 14
Atlanta 13
Hangzhou 13
Norwalk 13
Poplar 13
Zhengzhou 12
Boston 11
Denver 11
London 11
Pune 11
Ankara 10
Biên Hòa 10
Chennai 10
Frankfurt am Main 10
Redmond 10
Rome 10
The Dalles 10
Belo Horizonte 9
Chengdu 9
Chongqing 9
Naples 9
Wuhan 9
Dhaka 8
Fuzhou 8
Mestre 8
Ninh Bình 8
Palermo 8
Philadelphia 8
Phoenix 8
San Francisco 8
Seoul 8
Bangkok 7
Totale 7.051
Salva come PNG Salva come JPEG
Nome #
Are the Myeloma bone microevironment cells tumoral or not? 224
Ammonium Production and Glutamine-Addiction of Myeloma Cells: New Attractive Targets in Multiple Myeloma 221
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target 220
Bone marrow CX3CL1/Fractalkine is a new player of the pro-angiogenic microenvironment in multiple myeloma patients 215
HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients 195
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo 185
Activation of non-canonical wnt pathway in human mesenchymal cells affects osteogenic differentiation: a potential target in Multiple Myeloma microenvironment 184
CC-4047 (Pomalidomide) inhibits multiple myeloma-induced osteoclast formation targeting RANKL in the bone marrow microenvironment 183
Hypoxia and hypoxia inducible factor (HIF)-1α in Multiple Myeloma patients: role in the angiogenic switch 183
Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20 183
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation 182
Hypoxia-Inducible Factor (HIF)-1 alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo 179
HOXB7 is a key gene involved in Myeloma cell growth and Myeloma-induced angiogenesis in Multiple Myeloma patients 177
Hypoxia and Hypoxia Inducible Factor (HIF)-1{alpha} in Multiple Myeloma: Effect on the Pro-Angiogenic Signature of Myeloma Cells and the Bone Marrow Microenvironment 175
EXPRESSION OF CD38 AND ECTOENZYMES OF THE ADENOSINERGIC PATHWAYS IN MYELOMA BONE NICHE: A RATIONAL BASIS FOR THE USE OF DARATUMUMAB TO TARGET OSTEOCLAST FORMATION IN MULTIPLE MYELOMA 174
The Immunomodulatory drugs Lenalidomide and Pomalidomide inhibit multiple myeloma-induced osteoclast formation and RANKL/OPG ratio in myeloma microenvironment targeting the expression of adhesion molecules 168
Oxygen tension in the bone marrow (BM) of patients with malignant and indolent monoclonal gammopathy: role of hypoxia and hypoxia-inducible factor (HIF)-1{alpha} in the regulation of gene expression and pro-angiogenic profiles of CD138+ cells 167
Myeloma cells inhibit the non-canonical wnt co-receptor ror2 in human mesenchymal/osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on mm-induced impairment of the osteogenic differentiation process 161
The IMID CC-4047 (Pomalidomide) inhibits myeloma-induced osteoclast formation 160
Bortezomib improves bone integrity in multiple myeloma patients by blocking osteocyte death and autophagy 159
DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY 159
HOXB7 is critically involved in Multiple Myeloma-induced angiogenic switch 158
The homeobox gene HOXB7 regulates the production of pro-angiogenic molecole by myeloma cells and it is a target in myeloma-induced angiogenesis 157
Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin? 157
LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES 157
Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells 154
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts 154
Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity 153
In vitro and In vivo evidences of osteocytes involvement in myeloma-induced osteolysis 152
Use of traffic crash as a risk assessment scale in hospitalized seniors: A perspective observational study 151
Glutamine dependence and PIK3CA mutations in colon-rectal cancer cells: ATF4 enters the stage 148
Galectin-1 Is Highly Expressed By Myeloma Cells and the Bone Marrow Microenvironment and Its Suppression Delineates a New Therapeutic in Vitro and in Vivo Strategy in Multiple Myeloma 148
Non canonical wnt signal pathway (Wnt5a/ror2) activation stimulates the osteogenic differentiation process of bone mesenchymal cells being a potential target in multiple myeloma bone disease 147
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells 147
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties 146
Increased osteocyte apoptosis in Multiple Myeloma patients: a potential role in bone remodeling alterations related to osteolytic bone lesions 143
Angiogenesis and multiple myeloma 143
Bone marrow CD14+ cells show different transcriptional profiles in Multiple Myeloma (MM) as compared to smoldering MM and MGUS: overexpression of IL21R and its involvement in osteoclastogenesis 141
The link between bone microenvironment and immune cells in multiple myeloma: Emerging role of CD38 140
The osteoblastic niche in the context of multiple myeloma 138
Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation 138
Bone marrow monocyte / macrophage derived activin a mediates the osteoclastogenic effects of IL-3 in myeloma 138
Generation and Characterization of Microvesicles after Daratumumab Interaction with Myeloma Cells 138
Modulation of non canonical wnt5a/ror2 signaling pathway in human mesenchymal cells increases osteogenic differentiation counterbalancing the effect of myeloma cells 136
Lenalidomide Increases Human Dendritic Cell Maturation in Multiple Myeloma Modulating Both Monocyte Differentiation and Mesenchymal Stromal Cell Inhibitory Properties through Ikaros and Casein Kinase 1 Degradation, Respectively 134
Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients 133
Possible targets to treat myeloma-related osteoclastogenesis 133
Oncolytic Virotherapy in Multiple Myeloma: A Possible Alternative Role of Bovine Viruses 129
The anti-myeloma effect of Lenalidomide is increased by hypoxia-inducible factor (HIF)-1a inhibition in multiple myeloma cells both in vitro and in vivo 126
Validity and reliability of the Italian version of painad for postoperative pain assessment in geriatric patients with proximal femur fractures 125
Hypoxia-inducible factor (HIF)-1 is a therapeutic target in myeloma-induced angiogenesis and bone destruction in vitro and in vivo 125
Il mieloma multiplo nell'era dei nuovi farmaci. Patogenesi 122
Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma 119
Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with Multiple Myeloma bone disease 118
Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations 118
The activation of wnt5a-mediated non canonical wnt signaling in human bone marrow osteoprogenitor cells increases osteoblastogenesis and counterbalances the inhibitory effect of myeloma cells on ror2/fzd5 expression 115
Trascriptome Analysis of Bone Marrow CD14+ Monocytes Revealed Differential Expression Profiles in Symptomatic Multiple Myeloma (MM) Compared to Smoldering MM and Monoclonal Gammopathy of Undetermined Significance 115
Proteasome Inhibitors Block Myeloma-Induced Osteocyte Death in Vitro and in Vivo in Multiple Myeloma Patients 114
Relationship between bone imaging features and bone marrow cytokine and chemokine profiles in patients with monoclonal gammopathy 112
Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche 112
Relationship between skeletal involvement, cytogenetic features and bone marrow profiles of cytokines and chemokines in patients with monoclonal gammopathy 109
Hypoxia-Inducible Factor (HIF)-1a Is A Therapeutic Target in Myeloma-Induced Angiogenesis and Bone Destruction in Vivo 107
Bisphosphonates in multiple myeloma: Preclinical and clinical data. 105
Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction 105
Assessing satisfaction in simulation among nursing students: psychometric properties of the Satisfaction with Simulation Experience - Italian Version scale 103
Overexpression of Pro-Osteoclastogenic Cytokine Receptors and Chemokines By Bone Marrow CD14(+) Monocytes of Multiple Myeloma (MM) Patients As Compared to Smoldering MM (SMM) and Monoclonal Gammopathy of Uncertain Significance (MGUS): Role of Interleukin(IL)-21 Receptor/IL-21 Axis in MM-Induced Osteoclastogenesis 103
NAD⁺-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma Model 103
The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide 100
The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors 98
Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells 97
High ASCT2 activity as a marker of extracellular glutamine dependence in ammoniagenic multiple myeloma cell lines 96
The potential of inhibiting glutamine uptake as a therapeutic target for multiple myeloma 96
Interleukin-3 induces activin A in bone marrow monocytes: role in multiple myeloma patients 95
Transcriptional and proteomic profiles of bone marrow CD14+ cells in multiple myeloma (MM) compared to smoldering MM and MGUS: overexpression of Interleukin (IL)-21 receptor and its involvement in MM-induced osteoclastogenesis 95
Ectoenzymes and Their Products As Communicators in the Human Myeloma Niche 95
Proteasome inhibitors modulate osteocyte death and autophagy in multiple myeloma 93
Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD+ 92
Relationship between presence of osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: role of chemokine (C-C motif) ligand 20 91
Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules 90
The Myeloma Cells Escape from Bone Marrow to Skin Extramedullary Localization upon Bortezomib Resistance: Role of CXCR4 89
IL3 Induces Osteoclastogenesis In Vivo and Is Modulated By Bone Marrow Monocyte / Macrophage Derived Activin A 88
Myeloma-Induced osteocyte death was blunted by proteasome inhibitors through the modulation of autophagy 88
Hypoxia-Inducible Factor (HIF)-1α Is a Therapeutic Target in Myeloma-Induced Angiogenesis 83
New insights into osteogenic and chondrogenic differentiation of human bone marrow mesenchymal stem cells and their potential clinical applications for bone regeneration in pediatric orthopaedics 80
Mechanism of action of bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment: Impact on myeloma-induced alterations of bone remodeling 80
Evaluation of a New Automated Mono-Test for the Detection of Aspergillus Galactomannan: Comparison of Aspergillus Galactomannan Ag VirCLIA® Mono-Test with PlateliaTM Aspergillus Ag ELISA Assay 76
Role of osteocytes in myeloma bone disease: Anti-sclerostin antibody as new therapeutic strategy 75
Myeloma and osteoclast relationship 73
Over-expression of pro-osteoclastogenic cytokine receptors and chemokines by bone marrow CD14+ monocytes of Multiple Myeloma (MM) patients as compared to Smoldering MM (SMM) and Monoclonal Gammopathy of Uncertain Significance (MGUS): role of IL-21R/IL-21 axis in MM-induced osteoclastogenesis. 2
Totale 11.795
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.391
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.391
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202121 0 0 0 0 0 0 0 0 0 0 0 21
2021/2022402 7 1 8 42 12 8 36 37 29 40 32 150
2022/20231.687 199 193 124 109 131 183 47 107 519 24 41 10
2023/2024590 24 52 11 15 39 185 50 25 12 37 37 103
2024/20252.053 46 95 109 170 226 227 71 67 263 188 185 406
2025/20264.434 410 369 550 456 646 245 396 189 566 348 166 93
Totale 11.795